

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

**DATE OF BOARD MEETING
AND
UPDATE OF PUBLICATION OF AUDITED ANNUAL RESULTS**

Reference is made to the announcement of Sinco Pharmaceuticals Holdings Limited (the “**Company**”) dated 18 March 2020 in relation to the meeting of its board of directors (the “**Board**”) held on Monday, 30 March 2020 and the unaudited annual results announcement of the Company dated 30 March 2020.

The business of the Company and its subsidiaries (the “**Group**”) are substantially based in the People’s Republic of China (the “**PRC**”). Due to the travel and quarantine restrictions in the PRC relating to the COVID-19 pandemic, the audit process for the Company’s financial results for the year ended 31 December 2019 (the “**Year**”) has been affected.

The Board announces that another meeting of the Board will be held on Friday, 17 April 2020 for the purpose of, among other matters, considering and approving the audited annual results of the Group for the Year and its publication and to transact any other business, if any.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 3 April 2020

As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive directors of the Company are Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang.